Chimeric oncolytic adenovirus to break away from neutralizing antibodies.
作者信息
Sanchez Gil Judit, Fudaba Hirotaka, Wakimoto Hiroaki
机构信息
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Department of Neurosurgery, Oita University Faculty of Medicine, Yufu, Oita 879-5593, Japan.
出版信息
Mol Ther. 2024 Apr 3;32(4):875-877. doi: 10.1016/j.ymthe.2024.03.017. Epub 2024 Mar 20.
Abstract
摘要
相似文献
1
Chimeric oncolytic adenovirus to break away from neutralizing antibodies.嵌合溶瘤腺病毒以摆脱中和抗体。
Mol Ther. 2024 Apr 3;32(4):875-877. doi: 10.1016/j.ymthe.2024.03.017. Epub 2024 Mar 20.
2
Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.嵌合溶瘤腺病毒可逃避人类患者的中和抗体，并在免疫小鼠中表现出增强的抗胶质瘤疗效。
Mol Ther. 2024 Mar 6;32(3):722-733. doi: 10.1016/j.ymthe.2024.01.035. Epub 2024 Feb 3.
3
Modification of oncolytic adenovirus and its application in cancer therapy.肿瘤溶瘤腺病毒的修饰及其在癌症治疗中的应用。
Discov Med. 2020 Nov-Dec;30(161):129-144.
4
Chimeric Ad5/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency.嵌合型Ad5/35溶瘤腺病毒可克服预先存在的中和抗体并提高肿瘤靶向效率。
Cancer Gene Ther. 2025 Apr;32(4):418-436. doi: 10.1038/s41417-025-00884-x. Epub 2025 Mar 8.
5
Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.抗体的分子重定向将针对溶瘤病毒的免疫防御转化为癌症免疫疗法。
Nat Commun. 2019 Jul 19;10(1):3236. doi: 10.1038/s41467-019-11137-5.
6
Adenovirus-Neutralizing and Infection-Promoting Activities Measured in Serum of Human Brain Cancer Patients Treated with Oncolytic Adenovirus Ad5-∆24.RGD.在接受溶瘤腺病毒Ad5-∆24.RGD治疗的人脑癌患者血清中检测到的腺病毒中和及感染促进活性。
Int J Mol Sci. 2025 Jan 20;26(2):854. doi: 10.3390/ijms26020854.
7
Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy.基因工程细胞膜纳米囊泡用于溶瘤腺病毒递送：癌症病毒治疗的多功能平台。
Nano Lett. 2019 May 8;19(5):2993-3001. doi: 10.1021/acs.nanolett.9b00145. Epub 2019 Apr 12.
8
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11.具有透明质酸酶活性的逃避中和抗体的溶瘤腺病毒：VCN-11。
J Control Release. 2021 Apr 10;332:517-528. doi: 10.1016/j.jconrel.2021.02.035. Epub 2021 Mar 3.
9
Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy.通过肿瘤微粒将溶瘤腺病毒递送至致瘤细胞的细胞核用于病毒疗法。
Biomaterials. 2016 May;89:56-66. doi: 10.1016/j.biomaterials.2016.02.025. Epub 2016 Feb 23.
10
Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapy.溶瘤腺病毒载体在前列腺癌治疗中的嗜性和转导作用
Front Biosci (Landmark Ed). 2021 Oct 30;26(10):866-872. doi: 10.52586/4993.
本文引用的文献
1
Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.嵌合溶瘤腺病毒可逃避人类患者的中和抗体，并在免疫小鼠中表现出增强的抗胶质瘤疗效。
Mol Ther. 2024 Mar 6;32(3):722-733. doi: 10.1016/j.ymthe.2024.01.035. Epub 2024 Feb 3.
2
Clinical trial links oncolytic immunoactivation to survival in glioblastoma.临床试验将溶瘤免疫激活与胶质母细胞瘤的生存联系起来。
Nature. 2023 Nov;623(7985):157-166. doi: 10.1038/s41586-023-06623-2. Epub 2023 Oct 18.
3
Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?预先存在的免疫：对有效的溶瘤病毒治疗的障碍还是桥梁？
Cytokine Growth Factor Rev. 2023 Apr;70:1-12. doi: 10.1016/j.cytogfr.2023.01.002. Epub 2023 Jan 31.
4
Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus.HSV-1 预先存在的免疫增强新型免疫刺激溶瘤病毒的抗癌疗效。
Viruses. 2022 Oct 23;14(11):2327. doi: 10.3390/v14112327.
5
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.溶瘤病毒 DNX-2401 治疗儿童弥漫性内在脑桥胶质瘤。
N Engl J Med. 2022 Jun 30;386(26):2471-2481. doi: 10.1056/NEJMoa2202028.
6
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.溶瘤单纯疱疹病毒 1 型 G207 免疫病毒疗法治疗儿科高级别脑胶质瘤。
N Engl J Med. 2021 Apr 29;384(17):1613-1622. doi: 10.1056/NEJMoa2024947. Epub 2021 Apr 10.
7
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.规避抗病毒免疫以优化癌症病毒疗法的当前策略。
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2020-002086.
8
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.用于癌症治疗的溶瘤病毒：障碍与最新进展
Mol Ther Oncolytics. 2019 Nov 2;15:234-247. doi: 10.1016/j.omto.2019.10.007. eCollection 2019 Dec 20.
9
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.预先存在的对溶瘤病毒的免疫增强了其免疫治疗效果。
Mol Ther. 2018 Apr 4;26(4):1008-1019. doi: 10.1016/j.ymthe.2018.01.019. Epub 2018 Jan 31.
10
Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.接受腺病毒溶瘤免疫疗法治疗的癌症患者的预测性和预后临床变量
Mol Ther. 2016 Aug;24(7):1323-32. doi: 10.1038/mt.2016.67. Epub 2016 Apr 4.
Zotero 插件